Global Liver Institute Welcomes Larry R. Holden as CEO
September 03, 2024 09:54 ET
|
Global Liver Institute
Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...
Renown Health pioneers HistoSonics Edison system delivering histotripsy for non-invasive liver tumor treatment
August 08, 2024 16:18 ET
|
Renown Health
Reno, NEV., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Renown Health announced today that the first patients have received targeted liver tumor treatments through the Edison® System histotripsy technology,...
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 30, 2024 02:00 ET
|
CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
July 29, 2024 08:00 ET
|
CytoSorbents
CytoSorbents new modern website launch unifies corporate and product websites and highlights "Working to Save Lives Together"
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
April 09, 2024 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
[Latest] Global Liver Cancer Market Size/Share Worth USD 16.3 Billion by 2033 at a 14.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 03, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Liver Cancer Market Size, Trends and Insights By Type (Hepatocellular Carcinoma...
For Rare Liver Disease Patients, Care Transitions Pose Yet Another Risk
February 01, 2024 08:00 ET
|
Global Liver Institute
Washington, D.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Today marks the start of Global Liver Institute’s (GLI) 2024 #RareAware campaign, which calls attention to the more than 100 rare liver diseases...
[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 29, 2023 15:00 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Organ Transplantation Market Size, Trends and Insights By Product Type (Organ...